Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

SeleXel

SeleXel
2006 FOUNDED
PRIVATE STATUS
Accelerator/Inc LATEST DEAL TYPE
1 INVESTORS
Description

Developer of biotech solutions intended to treat invasive or metastatic cancers. The company develops a portfolio of molecules based on the RNA interference technology that inhibit very specifically the production of a protein playing a key role in the development or progression of cancer, enabling healthcare professionals to restore the ability of the immune system to eliminate the tumor.

Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Primary Office
  • Centre Pierre Potier
  • 1 place Pierre Potier Oncopole input B
  • 31100 Toulouse
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore SeleXel’s full profile, request a free trial.

SeleXel Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

SeleXel Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Agoranov Accelerator/Incubator 000 0000 000000 0

SeleXel Executive Team (3)

Name Title Board
Seat
Contact
Info
Pierre Attali MD Co-Founder & President
Florence Cabon Co-Founder

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »